Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 3
2010 1
2013 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Legendre CM, et al. N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981. N Engl J Med. 2013. PMID: 23738544 Free article. Clinical Trial.
BACKGROUND: Atypical hemolytic-uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. ...METHODS: We conducted two prospective phase 2 trials in which patients with atypical hemolyti
BACKGROUND: Atypical hemolytic-uremic syndrome is a genetic, life-threatening, chronic disease of complement-med …
Eculizumab in atypical hemolytic-uremic syndrome.
Tanimoto T, Oshima Y, Kami M. Tanimoto T, et al. N Engl J Med. 2013 Oct 3;369(14):1378-9. doi: 10.1056/NEJMc1308826. N Engl J Med. 2013. PMID: 24088109 Free article. No abstract available.
Eculizumab in atypical hemolytic-uremic syndrome.
Legendre CM, Licht C, Loirat C. Legendre CM, et al. N Engl J Med. 2013 Oct 3;369(14):1379-80. doi: 10.1056/NEJMc1308826. N Engl J Med. 2013. PMID: 24088105 Free article. No abstract available.
Eculizumab in atypical hemolytic-uremic syndrome.
Kistler AD. Kistler AD. N Engl J Med. 2013 Oct 3;369(14):1378. doi: 10.1056/NEJMc1308826. N Engl J Med. 2013. PMID: 24088108 Free article. No abstract available.
Eculizumab in atypical hemolytic-uremic syndrome.
Amadio A, Tejani AM. Amadio A, et al. N Engl J Med. 2013 Oct 3;369(14):1378. doi: 10.1056/NEJMc1308826. N Engl J Med. 2013. PMID: 24088107 Free article. No abstract available.
Eculizumab for atypical hemolytic-uremic syndrome.
Nürnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA, Kribben A, Zimmerhackl LB, Janecke AR, Nagel M, Kirschfink M. Nürnberger J, et al. N Engl J Med. 2009 Jan 29;360(5):542-4. doi: 10.1056/NEJMc0808527. N Engl J Med. 2009. PMID: 19179328 No abstract available.